Form 8-K - Current report:
SEC Accession No. 0000950170-24-106606
Filing Date
2024-09-16
Accepted
2024-09-16 07:00:12
Documents
34
Period of Report
2024-09-14
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K itos-20240914.htm   iXBRL 8-K 40781
2 EX-99.1 itos-ex99_1.htm EX-99.1 56100
3 EX-99.2 itos-ex99_2.htm EX-99.2 25541
4 GRAPHIC img229093814_0.jpg GRAPHIC 9280
5 GRAPHIC itos-ex99_2s1.jpg GRAPHIC 158443
6 GRAPHIC itos-ex99_2s2.jpg GRAPHIC 801509
7 GRAPHIC itos-ex99_2s3.jpg GRAPHIC 126430
8 GRAPHIC itos-ex99_2s4.jpg GRAPHIC 395781
9 GRAPHIC itos-ex99_2s5.jpg GRAPHIC 390439
10 GRAPHIC itos-ex99_2s6.jpg GRAPHIC 327682
11 GRAPHIC itos-ex99_2s7.jpg GRAPHIC 160497
12 GRAPHIC itos-ex99_2s8.jpg GRAPHIC 360762
13 GRAPHIC itos-ex99_2s9.jpg GRAPHIC 489171
14 GRAPHIC itos-ex99_2s10.jpg GRAPHIC 444356
15 GRAPHIC itos-ex99_2s11.jpg GRAPHIC 471993
16 GRAPHIC itos-ex99_2s12.jpg GRAPHIC 471094
17 GRAPHIC itos-ex99_2s13.jpg GRAPHIC 327117
18 GRAPHIC itos-ex99_2s14.jpg GRAPHIC 533418
19 GRAPHIC itos-ex99_2s15.jpg GRAPHIC 499457
20 GRAPHIC itos-ex99_2s16.jpg GRAPHIC 132919
21 GRAPHIC itos-ex99_2s17.jpg GRAPHIC 256853
22 GRAPHIC itos-ex99_2s18.jpg GRAPHIC 339097
23 GRAPHIC itos-ex99_2s19.jpg GRAPHIC 281334
24 GRAPHIC itos-ex99_2s20.jpg GRAPHIC 156420
  Complete submission text file 0000950170-24-106606.txt   10079368

Data Files

Seq Description Document Type Size
25 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT itos-20240914.xsd EX-101.SCH 24893
36 EXTRACTED XBRL INSTANCE DOCUMENT itos-20240914_htm.xml XML 4704
Mailing Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472
Business Address 321 ARSENAL STREET BLDG 312, FLOOR 3, SUITE 301 WATERTOWN MA 02472 857-204-4583
iTeos Therapeutics, Inc. (Filer) CIK: 0001808865 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39401 | Film No.: 241299295
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)